BioSpace News Archive

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update.

Pear Therapeutics, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD).

POINT Biopharma Global Inc. today announced that it will host a virtual education event titled “The First Principles of Radiopharmaceuticals” on Monday, December 6, 2021 at 12:00 pm ET.

Numinus Wellness Inc. will release its financial results for the quarter and year ended August 31, 2021 after market close on Thursday, December 9, 2021.

Vapotherm, Inc. today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Schrödinger today announced that management will participate virtually at the following investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference.

Moderna, Inc. today announced its participation in the following upcoming virtual investor conferences: NASDAQ 45th Investor Conference on Wednesday, December 1st at 9:30 a.m. ET.

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company’s common stock.

Lixte Biotechnology Holdings, Inc . announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated.